The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety

Menopause

Volumn 14, Issue 3, 2007, Pages 510-517

  Stovall, Dale W ^a   Utian, Wulf H ^b   Gass, Margery L S ^c   Qu, Yongming ^d   Muram, David ^d   Wong, Mayme ^d   Plouffe Jr , Leo ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b Rapid Medical Research   (United States)

^c Holmes Hospital   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Endometrial safety; Oral estradiol; Raloxifene; Vasomotor symptoms

Indexed keywords

ESTRADIOL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADRENERGIC SYSTEM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HOSPITALIZATION; HOT FLUSH; HUMAN; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; RALOXIFENE; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VASOMOTOR SYSTEM;

EID: 34447266932     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e318031a83d     Document Type: Article

References (22)

1. Armitage M, Nooney J, Evans S. Recent concerns surrounding HRT. Clin Endocrinol (Oxf) 2003;59:145-155.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
4. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004;11:589-600.
5. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006;119:S3-S11.
6. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118:163-165.
7. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629.
8. Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-565.
9. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-73.
10. Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L Jr. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Obstet Gynecol 2004;103:267-273.
11. Pinkerton JV, Shifren JL, La Valleur J, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10:45-52.
12. Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-352.
13. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol 2004;104:837-844.
14. Deleted in proof.
15. Kurman RJ, Norris HJ. Endometrial hyperplasia and related cellular changes. In: Blaustein's Pathology of the Female Genital Tract, 4th ed. New York, NY: Springer-Verlag, 1994:411-427.
16. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform J 1991;25:411-424.
17. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium - a pilot study. Menopause 2004;11:167-175.
18. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006;85:155-160.
19. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;(3):CD000402.
20. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004;291:1610-1620.
21. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761.
22. Cummings SR, Duong T, Kenyon E, Cauley J, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216-220.